Yuhan Corp. has discovered glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of obesity, diabetes, hypertension, hyperlipidemia, hypoglycemia, coronary artery disease, chronic kidney disease and cardiovascular disorders, as well as hepatic steatosis and alcoholic fatty liver disease.